A PYMNTS Company

US: FTC approves Teva-Allergan deal

By  |  July 28, 2016

Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to buy Allergan Plc’s generics business, after agreeing to divest 79 generic drugs to rival firms, the Federal Trade Commission on July 26.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The $40.5 billion deal was announced in July 2015 and further solidifies Teva’s position as the world’s leading manufacturer of generics while freeing Allergan to focus on branded drugs.

    Teva expects to close the transaction next week and has said that the combined company will have about 338 product registrations and will hold the leading position as the initial market entrant for around 115 pending U.S. generic drug applications.

    Full Content: CNBC

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.